Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Gene therapy improves gemcitabine effects in experimental glioma model


Attempts to improve the chemotherapeutic efficacy and radiotherapy-sensitivity of the anticancer agent, gemcitabine, using gene therapy have yielded interesting results in preclinical glioma models presented at the 13th European Cancer Conference (ECCO).

Investigators took the enzyme that activates gemcitabine, deoxycytidine kinase (dCK) and inserted it into a viral carrier – Ad-dCK. In vitro assay cells from mice, rats and humans, and mice infected with glioma (tumours originating from the spinal cord or brain) were then infiltrated with this gene therapy. Assay cells were subsequently treated with gemcitabine and irradiated. Tumour-bearing mice received an intraperitoneal injection of gemcitabine followed by local tumour irradiation. As gemcitabine is an anticancer agent with established efficacy, use of gene therapy to increase its enzymatic activation was hypothesised to offer potential improvements in chemo- and radiotherapy efficacy.

In vitro findings from the three different experimental glioma varied considerably. In the G1261 mouse cellular assay, increased levels of dCK enzyme activity failed to increase gemcitabine toxicity - although gemcitabine itself had a minor radiosensitising effect. Conversely, in rat C6 and 9L glioma cells, elevated dCK levels were found to substantially improve both gemcitabine toxicity and the radiosensitising effect.

Unsurprisingly, results from in vivo mouse studies mirrored the murine cellular assay findings. Although the combination of gemcitabine and radiotherapy had a pronounced synergistic effect, with 60% of animals tumour-free after 100 days compared to 0% on monotherapy, increased dCK levels did not impact on tumour growth or survival.

Experiments with C6 and 9L rat models are ongoing to further probe the promising increase in chemo- and radiosensitising effects of gemcitabine observed in response to elevated dCK levels. Ultimately, this gene therapy approach may open up avenues to increase the overall efficacy of chemotherapy and radiotherapy.

Speaking at ECCO 13, study author, Dr Katalin Lumniczky from the National Research Institute for Radiobiology, Budapest commented, "These results highlight the important and increasing role that gene therapy will hold for treatments in the future. Radiotherapy along with surgery, is the main therapeutic strategy in the treatment of most cancers. Our research aims to selectively increase radiosensitivity of tumour cells by the means of gene therapy. In this way tumour cells could respond better to conventional doses of radiation, resulting in higher tumour cell kill. This might have two main impacts on the patient. Firstly, patients having a radio-resistant tumour could be treated more successfully without the need to increase radiation doses. Secondly, it would even make it possible to reduce radiation doses in those patients whose normal tissues are known to be more radiosensitive than normal, and who, by this are at a high risk of developing long lasting side-effects after radiation which can substantially reduce their quality of life. Essentially, our research could help both in improving the success rate of radiotherapy and in reducing undesired side-effects."

About Gliomas

Half of all primary brain tumours (those originating from the brain and not from other parts of the body) are classified as gliomas. A glioma refers to a brain tumour that begins in glial, or supportive cells of the brain or spinal cord. There are four types of gliomas, astrocytoma, ependymoma and oligodendroglioma and mixed glioma (mixture of the other types).

The most common type are astrocytomas which develop from cells called astrocytes (type of cell that supports neurones). As with all types of gliomas, they are classified as either high grade or low grade. High grade tumours are malignant and difficult to treat whereas low grade tumours are slow growing and treatable.1

Unlike other cancers, the geographical incidence of brain tumours should be cautiously interpreted as the criteria and registration of brain tumours is not always consistent. However, the incidence does rise from the age of thirty, with males more likely to be diagnosed with gliomas than females with a ratio of 1.5:1.2

The causes of gliomas are largely unknown. By studying large numbers of patients, researchers have found certain risk factors that increase a person’s chance of developing gliomas . Some studies have shown that working in certain industries increases a person’s susceptibility to a glioma. Researchers are currently looking into the possibility of exposure to viruses as another possible cause and some scientists are investigating whether it might be hereditary. 3

Treatment options include surgery, radiotherapy and chemotherapy. Recently, there are a number of new anti-cancer treatments such as the anti-metabolites (interfere with the growth of cancer cells) e.g. gemcitabine, currently in clinical trials for possible treatment of gliomas.4

Kirsten Mason | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>